Pleiotropic effects of inhibitors of the RAAS in the diabetic population: Above and beyond blood pressure lowering

Current Diabetes Reports

Volumn 10, Issue 1, 2010, Pages 32-36

  Ismail, Haisam ^a   Mitchell, Rena ^b   McFarlane, Samy I ^b   Makaryus, Amgad N ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Diabetes; Renin angiotensin aldosterone system

Indexed keywords

ALISKIREN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; TELMISARTAN;

ALBUMINURIA; BLOOD VESSEL COMPLIANCE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCOAGULABILITY; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; PLEIOTROPY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 77249114746     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-009-0081-y     Document Type: Review

References (34)

1. VJ Dzau 2001 Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis Hypertension 37 1047 1052 1:CAS:528:DC%2BD3MXjtFejt70%3D 11304501
2. M Ushio-Fukai AM Zafari T Fukui, et al. 1996 p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells J Biol Chem 271 23317 23321 10.1074/jbc.271.38.23317 1:CAS:528:DyaK28XlvVCns7o%3D 8798532 (Pubitemid 26314775)
3. JB Laursen S Rajagopalan Z Galis, et al. 1997 Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension Circulation 95 588 593 1:CAS:528:DyaK2sXhsVCis7c%3D 9024144
4. SI McFarlane A Kumar JR Sowers 2003 Mechanisms by which angiotensin converting enzyme inhibitors prevent diabetes and cardiovascular disease Am J Cardiol 91 30H 37H 10.1016/S0002-9149(03)00432-6 1:CAS:528:DC%2BD3sXlsFGku7c%3D 12818733 (Pubitemid 36724893)
5. SI McFarlane M Banerji JR Sowers 2001 Insulin resistance and cardiovascular disease J Clin Endocrinol Metab 86 713 718 10.1210/jc.86.2.713 1:CAS:528:DC%2BD3MXht1Knt7s%3D 11158035 (Pubitemid 32207485)
6. S McFarlane 2009 Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials Expert Rev Cardiovasc Ther 7 1363 1371 10.1586/erc.09.115 1:CAS:528:DC%2BD1MXhtl2ksrvO 19900019
7. JR Sowers GL Bakris 2000 Antihypertensive therapy and the risk of type 2 diabetes mellitus N Engl J Med 342 969 970 10.1056/NEJM200003303421310 1:STN:280:DC%2BD3c7otlWjuw%3D%3D 10738057 (Pubitemid 30177059)
8. J Tuomilehto J Lindstrom JG Eriksson, et al. 2001 Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 344 1343 1350 10.1056/NEJM200105033441801 1:STN:280:DC%2BD3M3kvFejsA%3D%3D 11333990 (Pubitemid 32378388)
9. L Hansson LH Lindholm L Niskanen, et al. 1999 Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial Lancet 353 611 616 10.1016/S0140-6736(98) 05012-0 1:CAS:528:DyaK1MXivVCls78%3D 10030325 (Pubitemid 29087980)
10. S Yusuf P Sleight J Pogue, et al. 2000 Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 145 153 10.1056/NEJM200001203420301 1:STN:280:DC%2BD3c%2Fpt1emug%3D%3D 10639539 (Pubitemid 30051645)
11. LH Lindholm H Ibsen B Dahlof, et al. 2002 Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 1004 1010 10.1016/S0140-6736(02)08090-X 1:CAS:528: DC%2BD38XisV2htr0%3D 11937179 (Pubitemid 34286537)
12. S Kim H Iwao 2000 Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases Pharmacol Rev 52 11 34 1:CAS:528:DC%2BD3cXjvVWgtb4%3D 10699153
13. AN Makaryus SI McFarlane 2009 Treatment of hypertension in the diabetic patient Therapy 6 497 505 10.2217/thy.09.33 This is an up-to-date review article on the different medications used to treat hypertension
14. AV Chobanian GL Bakris HR Black, et al. 2003 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2560 2572 10.1001/jama.289.19. 2560 1:CAS:528:DC%2BD3sXjvFCqtrk%3D 12748199 (Pubitemid 37430158)
15. G Mancia G DeBaker A Dominiczak, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 28 1462 1536 17562668 This is an up-to-date guideline statement on the treatment of hypertension from the European Society of Cardiology
16. E Pimenta S Oparil 2009 Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors Ther Clin Risk Manag 5 459 464 19707255 This is a recent review article outlining recent studies on the benefits of aliskiren
17. H Gavras HR Brunner 2001 Role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure Hypertension 37 342 345 1:CAS:528:DC%2BD3MXhvVShtrg%3D 11230297
18. KK Griendling M Ushio-Fukai B Lassegue, et al. 1997 Angiotensin II signaling in vascular smooth muscle: new concepts Hypertension 29 366 373 1:CAS:528:DyaK2sXhsFOnsbc%3D 9039129
19. DN Muller EM Mervaala R Dechend, et al. 2000 Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy Am J Pathol 157 111 122 1:CAS:528:DC%2BD3cXlsVGmt74%3D 10880382
20. DN Muller R Dechend EM Mervaala, et al. 2000 NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats Hypertension 35 193 201 1:CAS:528:DC%2BD3cXpt1ajsQ%3D%3D 10642297
21. DE Vaughan SA Lazos K Tong 1995 Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis J Clin Invest 95 995 1001 10.1172/JCI117809 1:CAS:528:DyaK2MXktlKht7Y%3D 7884001
22. YQ Chen M Su RR Walia, et al. 1998 Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells J Biol Chem 273 8225 8231 10.1074/jbc.273.14.8225 1:CAS:528: DyaK1cXitlOisb8%3D 9525928 (Pubitemid 28168879)
23. J Schneiderman MS Sawdey MR Keeton, et al. 1992 Increased type plasminogen activator inhibitor gene expression in atherosclerotic human arteries Proc Natl Acad Sci U S A 89 6998 7002 10.1073/pnas.89.15.6998 1:CAS:528:DyaK38XlsVygtbw%3D 1495992
24. A Hamsten U de Faire G Walldius, et al. 1987 Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction Lancet 2 3 9 10.1016/S0140-6736(87)93050-9 1:STN:280:DyaL2s3ls1CgtQ%3D%3D 2885513
25. T Oikawa M Freeman W Lo, et al. 1997 Modulation of plasminogen activator inhibitor-1 in vivo: new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition Kidney Int 51 164 172 10.1038/ki.1997.20 1:STN:280:DyaK2s7kvV2jtw%3D%3D 8995730
26. N Winer MA Weber JR Sowers 2001 The effect of antihypertensive drugs on vascular compliance Curr Hypertens Rep 3 297 304 10.1007/s11906-001-0092-9 1:STN:280:DC%2BD3MvitV2ltQ%3D%3D 11470012
27. GM London B Pannier AP Guerin, et al. 1994 Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease: comparative effects of ACE inhibition and calcium channel blockade Circulation 90 2786 2796 1:STN:280:DyaK2M%2FoslWhsQ%3D%3D 7994822
28. A Natali G Pucci B Boldrini, et al. 2009 Metabolic syndrome: at the crossroads of cardiorenal risk J Nephrol 22 29 38 19229816 This is a recent article describing the effects of the cardiometabolic syndrome
29. EJ Lewis LG Hunsicker WR Clarke, et al. 2001 Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 851 860 10.1056/NEJMoa011303 1:CAS:528:DC%2BD3MXntlelsLg%3D 11565517 (Pubitemid 34940824)
30. BM Brenner ME Cooper D de Zeeuw, et al. 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861 869 10.1056/NEJMoa011161 1:CAS:528:DC%2BD3MXntlelsLk%3D 11565518 (Pubitemid 34940825)
31. R Agarwal 2001 Add-on angiotensin receptor blockade with maximized ACE inhibition Kidney Int 59 2282 2289 1:CAS:528:DC%2BD3MXks1Kluro%3D 11380832
32. CE Mogensen S Neldam I Tikkanen, et al. 2000 Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study BMJ 321 1440 1444 10.1136/bmj.321.7274. 1440 1:CAS:528:DC%2BD3MXjsFCkuw%3D%3D 11110735
33. AH Gradman R Kad 2008 Renin inhibition in hypertension J Am Coll Cardiol 51 519 528 10.1016/j.jacc.2007.10.027 1:CAS:528:DC%2BD1cXhsFygsLc%3D 18237679
34. CA Sanoski 2009 Aliskiren: An oral direct renin inhibitor for the treatment of hypertension Pharmacotherapy 29 193 212 10.1592/phco.29.2.193 1:CAS:528:DC%2BD1MXjtFGjsLc%3D 19170589 This is a recent article outlining the pharmacotherapy of aliskiren